tiprankstipranks
Trending News
More News >
Champions Oncology Inc (CSBR)
NASDAQ:CSBR
US Market

Champions Oncology (CSBR) Earnings Dates, Call Summary & Reports

Compare
134 Followers

Earnings Data

Report Date
Jul 17, 2025
TBA Not Confirmed
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.2
Last Year’s EPS
0.01
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Mar 11, 2025
|
% Change Since: -14.49%
|
Next Earnings Date:Jul 17, 2025
Earnings Call Sentiment|Positive
The earnings call reflected significant positive developments such as record-breaking revenue, successful data licensing, and improved financial metrics. However, challenges in the biotech sector and uncertainties regarding future data revenue contributions were highlighted. Despite the challenges, the company is optimistic about long-term growth.
Company Guidance
During the Champions Oncology Third Quarter Fiscal Year 2025 earnings call, CEO Ronnie Morris highlighted the company's record revenue of $17 million, driven by the closure of their first data deal. The core services business, anchored by their industry-leading PDX bank, continues to thrive. Morris noted a cautiously optimistic outlook for the biotech sector, despite a challenging environment. The demand for Champions' multiomic data set has increased, especially with the rise of AI, and the company is exploring ways to maximize its value. CFO David Miller reported that Q3 revenue reached $17 million, with research service revenue at $12.5 million and data revenue at $4.5 million. The gross margin improved to 61%, thanks to high-margin data revenue. Operating expenses decreased, contributing to a record adjusted EBITDA of $5.2 million. Despite short-term volatility, the company reaffirmed its full-year revenue growth guidance of 10% to 15%, focusing on expanding its data business and enhancing profitability.
Record-Breaking Revenue and Growth
Champions Oncology had a record-breaking quarter with total revenue surpassing $17 million and adjusted EBITDA hitting a record high. Research service revenue was $12.5 million, an increase from $12 million in the same period last year. The company reported adjusted EBITDA of $5.2 million compared to an adjusted loss of $1.7 million in the prior year.
Successful Data Licensing Agreement
Champions Oncology successfully completed its first data licensing deal, marking the initial validation of its strategic vision to create a transformative data business. Data revenue contribution was $4.5 million, showcasing early traction of the new platform.
Improved Financial Metrics
On a GAAP basis, income from operations was $4.5 million compared to a loss of $2.6 million in the prior year. Total gross margin improved to 53% compared to 40% in the same period last year. Research service margins also improved to 48% compared to 35% in the same period last year.
Strong Cash Position
Champions Oncology ended the quarter with $3.2 million of cash on the balance sheet and no debt. Cash generated by operating activities was $900,000.
---

Champions Oncology (CSBR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CSBR Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 17, 20252025 (Q4)
-0.20 / -
0.01
Mar 11, 20252025 (Q3)
-0.01 / 0.36
-0.16325.00% (+0.52)
Dec 11, 20242025 (Q2)
0.01 / 0.05
-0.15133.33% (+0.20)
Sep 11, 20242025 (Q1)
-0.03 / 0.11
-0.16168.75% (+0.27)
Jul 18, 20242024 (Q4)
-0.16 / 0.01
-0.17105.88% (+0.18)
Mar 12, 20242024 (Q3)
-0.06 / -0.16
-0.160.00% (0.00)
Dec 12, 20232024 (Q2)
-0.16 / -0.15
0.01-1600.00% (-0.16)
Sep 13, 20232024 (Q1)
-0.10 / -0.16
0
Jul 24, 20232023 (Q4)
-0.08 / -0.17
-0.02-750.00% (-0.15)
Mar 15, 20232023 (Q3)
-0.03 / -0.16
0.07-328.57% (-0.23)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

CSBR Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 11, 2025$8.90$9.79+10.00%
Dec 11, 2024$5.84$5.16-11.64%
Sep 11, 2024$4.07$4.46+9.58%
Jul 18, 2024$4.92$5.04+2.44%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Champions Oncology Inc (CSBR) report earnings?
Champions Oncology Inc (CSBR) is schdueled to report earning on Jul 17, 2025, TBA Not Confirmed.
    What is Champions Oncology Inc (CSBR) earnings time?
    Champions Oncology Inc (CSBR) earnings time is at Jul 17, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CSBR EPS forecast?
          CSBR EPS forecast for the fiscal quarter 2025 (Q4) is -0.2.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis